抗HIV治疗失败后HIV1耐药基因的变异
作者:
作者单位:

作者简介:

路新利

通讯作者:

中图分类号:

R512.91

基金项目:

河北省科学技术研究与发展计划(08276101D-92)


Drug resistance variation in HIV1 after the failure of highly active antiretroviral therapy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 文章评论
    摘要:

    目的研究抗人免疫缺陷病毒(HIV)治疗失败后,HIV1遗传基因变异情况,并分析其耐药性。方法选取抗HIV治疗失败的57例患者(其中采用D4T/3TC/NVP治疗方案者45例,3TC/AZT/NVP方案者7例,3TC/TDF/克立芝方案者5例),从其血浆中提取病毒RNA,运用逆转录-聚合酶链反应(RTPCR)和套式PCR扩增HIV1 pol区基因片段,并对扩增的目的片段进行测序,将测序结果提交Web站点(http://HIVdb.stanford.edu),分析耐药变异情况。结果3种治疗方案治疗失败者均出现耐药。57例患者,7例发生针对蛋白酶抑制剂的位点变异,其中1例(1.75%)M46IM蛋白酶抑制剂的位点变异,导致了抗ATV/r、FPV/r、IDV/r、LPV/r的潜在低度耐药和抗NFV的高度耐药;32例(56.14%)患者体内HIV1发生了逆转录酶基因变异,且均对不同逆转录酶抑制剂产生了耐受性,其中14例(43.75%,14/32)患者对斯坦福数据库中的11种药物全都耐药,且11例(78.57%)治疗方案为D4T/3TC/NVP。TDF、克立芝等二线药物的治疗方案突变位点少于一线药物D4T、3TC、NVP、AZT。结论耐药变异是导致抗HIV治疗失败的主要原因。在开展抗病毒治疗过程中,应适时进行耐药性检测,以获得较好疗效。

    Abstract:

    ObjectiveTo study genetic variation and drugresistance of HIV1 after the failure of highly active antiretroviral therapy(HAART) in HIV1/AIDS patients.MethodsFiftyseven patients with HAART failure, including 45 with D4T/3TC/NVP regime,7 with 3TC/AZT/NVP,and 5 with 3TC/TDF/ LPV/r, were enrolled in the study, viral RNA was extracted from plasma, partial HIV1pol gene was amplified by reverse transcription polymerase chain reaction(RTPCR)and nested PCR,and the amplified fragment was sequenced,the phylogenesis of sequences were analyzed by landing the websites http://HIV1db.stanford.edu., and drug resistance variation was analyzed.ResultsPatients with the failure of 3 types of therapeutic regimes all developed drug resistance. Among 57 patients, drugresistant variation in protease inhibitors(PIs) was identified in 7 patients, 1 of whom (1.75%)produced variation in M46IM which resulted in lowlevel resistance to ATV/r,FPV/r,IDV/r,LPV/r and highlevel resistance to NFV; Drugresistant variation in reverse transcriptase inhibitors (RTs) was identified in 32 patients(56.14%),and 14 (43.75%,14/32)of whom had resistance to 11 kinds of inhibitors(//HIV1db.stanford.edu),11 (78.57%,11/14) cases were with the regime of D4T/3TC/NVP. Mutation site in patients with secondline drugs(TDF,LPV/r)were less than firstline drugs(D4T,3TC,NVP,AZT). ConclusionDrug resistance variation is the major cause of failure of HIV1 therapy, drug resistance should be monitored during the course of antiHIV therapy.

    参考文献
    相似文献
引用本文

赵宏儒,路新利,李岩,等.抗HIV治疗失败后HIV1耐药基因的变异[J]. 中国感染控制杂志,2013,12(4):247-250. DOI:10.3969/j. issn.1671-9638.2013.
ZHAO Hongru, LU Xinli, LI Yan, et al. Drug resistance variation in HIV1 after the failure of highly active antiretroviral therapy[J]. Chin J Infect Control, 2013,12(4):247-250. DOI:10.3969/j. issn.1671-9638.2013.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2012-11-10
  • 最后修改日期:2013-02-12
  • 录用日期:
  • 在线发布日期: 2013-07-30
  • 出版日期: